The work, led by Sabah Noor with Nabeela Kousar, Khalil Ur Rehman and Wasfi Shatanawi, models blood as a so-called special third-grade fluid, a class of viscoelastic liquid whose stress response includes higher-order nonlinear terms. That choice matters. At low shear rates blood does not behave like water; its resistance to flow changes as it is continuously deformed by beating cilia and the sliding motion of an endoscope. Simpler non-Newtonian models such as Casson, Maxwell, Jeffrey or second-grade fluids can each capture one aspect of this behavior—yield stress, relaxation, or linear elasticity—but none account for the additional nonlinear elastic response that emerges under the complex, sustained deformation that characterizes cilia-driven endoscopic transport. The third-grade model, the authors argue, is the smallest framework that can represent these effects realistically.

The geometry of the problem is deliberately faithful to physiology. Two coaxial cylinders form the flow domain: the outer tube carries cilia on its inner surface, and these cilia beat asynchronously with a continuous phase lag between neighbors, producing a metachronal wave that travels along the wall. Depending on whether the wave and the effective stroke travel in the same or opposite directions, the beating is classified as symplectic or antiplectic—the former seen in the protozoan Opalina, the latter in Paramecium. Inside sits the endoscope, a solid rigid tube that moves axially at a fixed velocity, sweeping fluid along with it through the no-slip condition at its wall. Fluid occupies the gap between the two, bounded by constant-temperature walls that create a thermal gradient driving heat transfer.

On top of this mechanical picture, the researchers superimposed several physical effects that previous studies had treated only one at a time. An external radial magnetic field acts on the electrically conductive blood, generating Lorentz forces that oppose motion—the essence of magnetohydrodynamics, a field first described by Hannes Alfvén. The outer wall is treated as a porous medium, mimicking the permeability of biological tissue, which matters for predicting how fluid and suspended nanoparticles are absorbed into surrounding structures. Thermal radiation is included through the Roseland approximation, which is relevant for laser and thermal therapies where internal heat management is critical. And blood itself is transformed into a hybrid nanofluid by suspending two kinds of nanoparticles: zinc oxide (ZnO) and aluminum oxide (Al₂O₃).

The choice of nanoparticles is not arbitrary. ZnO offers chemical stability, low toxicity, antimicrobial activity, and proven biocompatibility, and it is already investigated for drug delivery, biosensing, and antiviral or anticancer applications. Al₂O₃ brings high thermal conductivity, corrosion resistance, and the ability to target specific tissues, improving treatment efficiency while limiting side effects. Combined at low volume fractions—no more than about three percent to avoid agglomeration and excessive viscosity—the two particles enhance heat transport while keeping the suspension stable enough for biomedical use. Blood’s ionic solution serves as the carrier fluid, with effective properties such as viscosity, density, thermal conductivity, and electrical conductivity computed through established hybrid-nanofluid mixing rules.

Perhaps the most significant departure from earlier work is the treatment of inertia. Most prior models of ciliary and peristaltic transport assumed creeping flow—negligible Reynolds number—which strips the governing equations of inertial terms. Here, the authors retained a moderate Reynolds number, between roughly 5 and 15, which is realistic for blood flow in larger vessels and keeps the momentum equations closer to their full form. Combined with the nonlinear shear-thickening rheology of the third-grade model, this produces a coupling among momentum transport, magnetic damping, porous drag, and heat transfer that simply cannot appear in creeping-flow formulations using conventional fluids. The cilia length parameter, wave number, and eccentricity of the elliptical ciliary stroke all enter directly through the boundary conditions at the outer wall, anchoring the mathematics to the actual beating motion of the biological structures.

Solving the resulting system of coupled nonlinear partial differential equations required a regular perturbation approach, carried out in two stages with the help of Mathematica. First, the equations were expanded in powers of the small wave number; then, because the axial momentum equation remained nonlinear even at zeroth order, a second perturbation was applied in the small third-grade parameter. The validity ranges—wave number and third-grade parameter both between 0.01 and 0.03—are small enough that neglected higher-order terms stay negligible. Residual analysis confirms convergence: maximum absolute errors were on the order of 10⁻⁶ to 10⁻⁸ for radial velocity, axial velocity, temperature, and pressure, indicating that the truncated series accurately approximates the true solution within its regime of validity.

The results reveal a rich interplay of competing mechanisms. Radial velocity falls as the radius ratio increases—the annular gap narrows, geometric confinement suppresses ciliary motion, and mass conservation forces the radial component to shrink—but rises dramatically with wave number and with cilia length, because longer cilia and shorter-wavelength metachronal waves transfer more momentum from wall to fluid. Doubling the wave number increased radial velocity by roughly 166 percent, and lengthening cilia by a modest fraction boosted it by nearly 87 percent. A faster-moving endoscope, by contrast, pushes fluid axially and weakens radial displacement.

Axial velocity behaves differently. It increases with radius ratio—momentum transfer from the moving endoscope intensifies in the confined space—and climbs steeply with wave number, roughly 200 percent over the studied range. Higher permeability of the porous wall reduces Darcy resistance and lets the fluid move more freely, raising axial speed by about a third, while a stronger magnetic field cuts axial velocity by roughly 30 percent as Lorentz forces impose electromagnetic drag. Notably, increasing the third-grade parameter raised axial velocity by about 60 percent: the nonlinear elastic stress terms let the fluid store deformation energy during ciliary pumping and endoscope motion and then release it back into the flow, facilitating axial momentum transport.

Temperature shows non-monotonic behavior in several cases. Increasing the third-grade parameter roughly doubles fluid temperature because enhanced axial motion strengthens convective heat transport from the hot wall. Permeability first raises temperature and then lowers it beyond a threshold, as convective retention of heat within the fluid gives way to radiative transfer toward the cooler wall. Magnetic field strength first cools the fluid by about 100 percent—Lorentz damping slows circulation—and then warms it again as heat accumulates in a stagnating fluid. Faster endoscope motion and higher Reynolds number both raise temperature by strengthening convection, while increasing the radiation parameter lowers it by distributing heat more uniformly.

Pressure responds as expected from the momentum balance. Stronger magnetic fields and larger third-grade parameters demand steeper pressure gradients to sustain flow—pressure rose 2.6 percent and 66 percent respectively across the tested ranges—while greater permeability and Reynolds number reduce the pressure needed. The team also examined bolus entrapment, the formation of recirculating fluid pockets trapped inside closed streamlines that travel with the metachronal wave. Bolus size grows with permeability and third-grade elasticity, because faster, more elastic fluid circulates more within each closed streamline, but shrinks under magnetic damping, which suppresses the overall velocity and traps less volume per pumping cycle.

The authors are candid about the model’s boundaries: velocity-slip and thermal-slip at the walls are neglected, the analysis is axisymmetric, and thermophysical properties are held constant. The perturbation solution is valid only for small wave numbers and weak third-grade effects, and stronger flows would require numerical methods. Even so, by uniting endoscope motion, magnetohydrodynamics, porous media, thermal radiation, ciliary propulsion, nonlinear blood rheology, and moderate inertia in a single analytically tractable framework, the study offers a physiologically grounded toolkit for designing magnetically controlled drug delivery, optimizing thermal therapies during endoscopy, and predicting how engineered nanoparticles will behave in the body’s ciliated passages. In an era when targeted nanomedicine is moving from bench to bedside, understanding these coupled transport physics is not an academic luxury—it is a prerequisite for safe and effective treatment.

The authors’ premise is disarmingly simple: obesity care has always been a logistics problem as much as a metabolic one. Conventional face-to-face programs work, but their benefits decay quickly, and commercial weight-loss schemes have never convincingly delivered long-term results. Trials that reduced the frequency of patient contact made outcomes worse, not better, because accountability and personalized feedback — the most fragile elements of any weight-management program — are precisely what thin out when clinic time is scarce. Smart technology, the review argues, can keep those components intact while cutting cost and provider time, and it can compensate for a well-documented gap: many primary care providers report inadequate training in psychological and behavioral counseling, the very skills obesity care demands. For any tool to qualify, the authors propose a seven-part test — it must be adaptable, affordable, accessible, accurate, intuitive, sustainable and scalable.

The review begins by dismantling the number most patients live by. Body mass index, long the gatekeeper of obesity diagnosis, is now formally considered insufficient: the Lancet Diabetes and Endocrinology Commission and the European Association for the Study of Obesity have both concluded that weight and height cannot distinguish fat from muscle, or visceral from subcutaneous fat, and that body-fat percentage varies with age, sex and ethnicity at any given BMI. Visceral adiposity — the metabolically active fat around the internal organs — can rise dangerously in people whose BMI barely moves, degrading insulin sensitivity and seeding diabetes. The Endocrine Society of India now classifies a BMI of 23 to 24.9 kg/m² as overweight and anything above 25 kg/m² as obese. Filling the diagnostic gap are convolutional neural networks: deep-learning architectures trained on magnetic resonance imaging, computed tomography and dual-energy X-ray absorptiometry scans that automatically segment and quantify visceral fat, subcutaneous fat and ectopic fat deposited inside organs. These AI-derived body-composition fingerprints predict cardiovascular events more effectively than BMI alone.

The pharmacological section reads like a dossier of record-breaking trials. In the phase 3b STEP UP trial, 1407 adults with obesity but without diabetes were randomized five-to-one-to-one to once-weekly injectable semaglutide at 7.2 mg, the established 2.4 mg dose, or placebo, alongside lifestyle intervention, and followed for 72 weeks. The higher dose removed 18.7 percent of body weight, versus 15.6 percent for 2.4 mg and 3.9 percent for placebo. Patients on 7.2 mg were 1.8 times more likely to lose a fifth of their weight and 2.4 times more likely to lose a quarter, and although gastrointestinal side effects were more frequent, serious adverse events were less common than at the lower dose, affecting 6.8 percent versus 10.9 percent of participants. For needle-averse patients, the OASIS 4 study tested oral semaglutide at 25 mg daily across 22 sites in four countries: after 71 weeks, participants had lost 13.6 percent of their body weight against 2.2 percent with placebo, with measurable gains in physical-function quality of life.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, delivered the year’s most consequential head-to-head result. In the open-label SURMOUNT 5 trial, adults with obesity received either the maximum tolerated dose of tirzepatide, 10 or 15 mg weekly, or the maximum tolerated dose of semaglutide, 1.7 or 2.4 mg weekly, for 72 weeks. Tirzepatide produced 20.2 percent mean weight loss against 13.7 percent for semaglutide. Its reach extended beyond the scale: in the SUMMIT trial, 731 patients with heart failure with preserved ejection fraction and a BMI of at least 30 were followed for up to 104 weeks, and cardiovascular death or a worsening heart-failure event occurred in 9.9 percent of the tirzepatide group versus 15.3 percent on placebo, a hazard ratio of 0.62. In the phase 2 SYNERGY NASH trial, biopsy-confirmed fatty liver disease with moderate-to-severe fibrosis resolved in 44, 56 and 62 percent of patients receiving 5, 10 and 15 mg of tirzepatide respectively, versus 10 percent on placebo — hinting at a single weekly injection that treats the liver as well as the waistline.

Behind the headline drugs, an invisible layer of artificial intelligence is reshaping who gets treated and when. Supervised machine-learning models — logistic regression, random forests and gradient boosting machines — sift electronic medical records, combining demographics, medical history, laboratory values, medication lists and social determinants of health into obesity-risk scores. One model built on birth records, pediatric growth charts and family history predicted early childhood obesity accurately in more than 85 percent of cases, and newer versions fold in sleep patterns, screen-time exposure and neighborhood characteristics. Transformer-based natural language processing — the BERT and GPT family of models behind modern chatbots — now mines unstructured clinical notes for dietary patterns, activity levels and psychosocial red flags that structured billing codes never capture. Linked to fitness trackers and calorie-counting apps, such algorithms can catch the earliest lifestyle drifts that precede weight gain. The authors are candid about the caveats: diagnostic algorithms can inherit demographic bias, and informed consent, algorithmic fairness, safety and data privacy remain legally unsettled.

Surgery, too, has been shrinking. Endoscopic sleeve gastroplasty, the flagship of a growing family of endoluminal techniques, uses a suturing device threaded through the mouth to fold and shrink the stomach, altering gastric physiology with no external incisions. Multicenter series and randomized data show clinically meaningful total and excess weight loss at 6 to 24 months, an acceptable safety profile and faster recovery than laparoscopic sleeve gastrectomy, making it attractive for patients with class I to II obesity — a BMI between 30 and 40 — or as a bridge therapy for higher-risk candidates, though long-term durability remains under study. Robotic-assisted bariatric surgery brings tremor-filtered instruments, enhanced articulation and three-dimensional vision to the operating table. The evidence is more equivocal: some registries show comparable or better outcomes, including reduced bleeding, while systematic reviews consistently report longer operative times and higher costs without reliable reductions in complications. Robots, the review concludes, currently earn their keep mainly in technically demanding or revisional operations.

The review’s most striking material concerns virtual reality, which the authors treat not as a gadget but as a clinical instrument. A head-mounted display does not merely show an image; it replaces the user’s world, generating “presence” — the felt sense of being physically inside a simulation — and with it control over sensory exposures no clinic could stage. The theoretical core is the allocentric lock hypothesis: the brain stores the body in two reference frames, an egocentric one built from proprioceptive and interoceptive sensation and an allocentric one anchored to external space. In long-standing obesity, the brain can become locked into a rigid, negative allocentric memory of the body, so that a patient who has lost 20 kilograms still perceives themselves as heavy — a mismatch that breeds behavioral exhaustion and relapse. Virtual embodiment exercises are designed to fuse the two frames and unlock that memory. In a study of virtual reality cue exposure therapy for binge eating and bulimia, 100 percent of patients achieved abstinence from purging immediately after treatment and maintained it for seven months, against roughly 75 percent for standard cognitive behavioral therapy. Over one year, 48 percent of the VR-enhanced group maintained or improved their weight loss, versus 29 percent for cognitive behavioral therapy and 11 percent for standard inpatient care, an odds ratio of 7.03.

Virtual reality also extends to metabolism. So-called exergames such as Supernatural, Beat Sabre and FitXR push players through full-body workouts, and studies using indirect calorimetry — the gold standard for measuring energy expenditure — confirm genuinely vigorous effort, with many sessions exceeding six metabolic equivalents of task, the threshold for vigorous activity. Yet the numbers on patients’ wrists are unreliable: waist-worn accelerometers miss 45 to 65 percent of the energy burned in virtual reality because the workouts emphasize arm movements and static squats that sensors read as standing still, while wrist-worn devices overestimate expenditure by 108 to 112 percent. Clinicians should steer patients toward chest-strap heart-rate monitors or simple ratings of perceived exertion. The same sober accounting applies to the technology’s obstacles: cybersickness from conflict between the eyes and the vestibular system, the digital divide that puts room-scale systems — which demand an unobstructed two-by-two-meter area — beyond many households, missing billing codes and thin long-term evidence. Meanwhile, the unglamorous infrastructure of digital care keeps proving itself: interactive voice response systems improve follow-up rates among patients with limited digital literacy; app-based interventions succeed when frequent self-monitoring is paired with human coaching or evidence-based algorithms; continuous glucose monitors are being repurposed as biofeedback and dietary-adherence tools, with a scoping review of 31 studies finding 93 percent deployed them to track glycemic variability; and randomized trials show telehealth achieves short-term weight loss non-inferior to in-person programs. Regulatory change is afoot too, as the FDA’s prescription digital therapeutics category opens a path for software that can be prescribed and reimbursed like a drug.

The review closes with a warning about the data plumbing underneath it all. Many consumer apps and devices sit outside traditional health-care privacy regimes, and patients consistently voice concern about confidentiality, data sharing and commercial secondary use of their health information. The authors call for privacy-by-design architectures, transparent consent policies, secure cloud systems, federated analytics that keep data on the device, and explicit informed consent whenever third-party platforms touch clinical care. The authors are equally candid about their own analysis: the technologies surveyed are heterogeneous, real-world trial evidence is scarce, and a field moving this quickly will always outrun any snapshot of it. Still, the verdict is confident. Mobile health, eHealth and telemedicine are no longer experiments at the margins of obesity medicine but functioning parts of it, and the decisive task ahead is no longer invention but translation — carrying these results into practice, so that the technology which helped make obesity a global epidemic can be conscripted to help end it.